Application Note: Structural basis for driving HER2-addicted cancer cells into apoptosis
16 September 2013

Patients do already benefit from several anti-HER2 drugs like the monoclonal antibodies trastuzumab (Herceptin®) and pertuzumab (Perjeta®), which have been shown in vitro to act only as a cytostatic agent, but not as a cytotoxic agent.

New HER2-binders employing alternative mechanisms to abolish HER2-dependent signaling and causing cytotoxic effects could expand and complement existing anti-HER2 therapies.

Download PDF >>PDF Icon

Read the full article...

  Become a member
  • Quick and complete access to all application articles

  • Download 10,000+
    applications and methods

  • Make informed buying decisions

Already a member?

Log in for full access to the article

Remember me